Keyphrases
End-stage Renal Disease
100%
Incretin Hormones
100%
Endocrine Pancreas
100%
Glucagon-like
42%
Glucose-dependent Insulinotropic Polypeptide
42%
Glucagon
42%
End-stage Renal Disease Patients
42%
Placebo
28%
Hyperglycemia
28%
Impaired Glucose Tolerance
28%
High Prevalence
28%
Euglycemia
28%
Plasma Parameters
14%
Healthy Controls
14%
Plasma Glucose
14%
Insulin
14%
Disease Groups
14%
Glucose Homeostasis
14%
Oral Glucose Tolerance Test
14%
Hormone Concentration
14%
Glucose Effect
14%
Insulin Release
14%
Hyperinsulinemic-euglycemic Clamp
14%
Hyperglycemic Clamp
14%
Insulin Concentration
14%
Infusion Rate
14%
Chronic Hemodialysis
14%
Regulating Effect
14%
Endocrine Pancreatic Function
14%
Medicine and Dentistry
Incretin
100%
End Stage Renal Disease
100%
Endocrine Pancreas
100%
Glucagon Like Peptide 1
30%
Gastric Inhibitory Polypeptide
30%
Glucagon
30%
Placebo
20%
Impaired Glucose Tolerance
20%
Prevalence
20%
Hyperglycemia
20%
Infusion
10%
Glucose Homeostasis
10%
Insulin Release
10%
Oral Glucose Tolerance Test
10%
Hemodialysis
10%
Infusion Rate
10%
Pancreas Function
10%
Biochemistry, Genetics and Molecular Biology
Incretin
100%
Glucagon-Like Peptide-1
50%
Gastric Inhibitory Polypeptide
50%
Glucagon
50%
Hyperglycemia
33%
Impaired Glucose Tolerance
33%
Prevalence
33%
Glucose Blood Level
16%
Glucose Homeostasis
16%
Insulin Release
16%
Hemodialysis
16%
Glucose Test
16%
Glucose Tolerance Test
16%
Hormone Blood Level
16%
Pancreas Function
16%
Neuroscience
Incretin
100%
Endocrine Pancreas
100%
Glucagon-Like Peptide-1
50%
Glucagon
50%
Gastric Inhibitory Polypeptide
50%
Placebo
33%
Hyperglycemia
33%
Glucose Tolerance Test
16%
Pharmacology, Toxicology and Pharmaceutical Science
Incretin
100%
End Stage Renal Disease
100%
Glucagon
30%
Gastric Inhibitory Polypeptide
30%
Glucagon-Like Peptide-1
30%
Placebo
20%
Prevalence
20%
Hyperglycemia
20%
Impaired Glucose Tolerance
20%
Hemodialysis
10%